Faeth Therapeutics
FTH
19 hedge funds and large institutions have $1.32M invested in Faeth Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
1% more capital invested
Capital invested by funds: $1.31M → $1.32M (+$13.5K)
0.37% more ownership
Funds ownership: 8.4% → 8.77% (+0.37%)
17% less funds holding
Funds holding: 23 → 19 (-4)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$30.9K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$21.7K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$3.66K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$73 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$18.3K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$11.5K |
| 3 |
LWL
Leo Wealth LLC
Hurst,
Texas
|
-$9.21K |
| 4 |
Renaissance Technologies
New York
|
-$5K |
| 5 |
BlackRock
New York
|
-$4.82K |
FTH Hedge Fund Activity: Q3 2024 in Review
19 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q3 2024, worth a combined $1.32M — up 1% from $1.31M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FTH and 1 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $55.2K. The largest seller was Bridgeway Capital Management, cutting an estimated $18.3K.
- 19 institutional investors held Faeth Therapeutics (FTH) as of Q3 2024, down from 23 in Q2 2024.
- Funds reported $1.32M of Faeth Therapeutics stock for Q3 2024, up 1% quarter-over-quarter.
- 1 fund opened new Faeth Therapeutics positions in Q3 2024 and 5 closed out, a net change of -4 holders.
- The largest Faeth Therapeutics buyer in Q3 2024 was Susquehanna International Group, an estimated $55.2K added.
- The largest Faeth Therapeutics seller in Q3 2024 was Bridgeway Capital Management, an estimated $18.3K sold.
Based on aggregated 13F filings for Q3 2024.